Details of Sustainability Topics

Taiyo Nippon Sanso Corporation (TNSC) has commenced joint development with YMC Co., Ltd., on a full process from synthesis to refinement for difficult-to-express proteins,* which are expected to see demand in the biomedical field. As the protein market expands in the biomedical field, there is a growing demand for difficult-to-express proteins that cannot be easily expressed using traditional expression and purification techniques using live cells. Looking ahead, joint development using TNSC’s cell-free protein synthesis technology and YMC’s strengths in chromatography technology will enable them to supply customers in the drug discovery research reagent market and the biomedical market with products that are optimized for cost and quality. The two companies will strengthen their collaboration not only in the manufacture of difficult to express proteins through cell-free protein synthesis systems, but also in various other fields, such as the development of high-performance affinity columns, by maximizing their respective strengths in the process from synthesis to purification.

*Difficult-to-express proteins: Proteins that are difficult to produce in a form that functions correctly